Rock Creek Advisors (the “Sale Agent”) is contacting you regarding the sale of assets of Sequencing Health, Inc (the “Company”).
Sequencing Health, Inc. (“Company”) is a company in the genomic sequencing space formed in 2022 in connection with the acquisition of the assets and IP of Genapsys, Inc. Genapsys and Sequencing Health together raised over $250M in capital since founding, which has been used to develop their innovative and proven semiconductor-based technology.
This technology enables high accuracy sequencing for short-read applications. Their genomic sequencing products are intended to provide flexibility and scalability at an affordable cost and with a small benchtop-instrument footprint. The technology is protected by a robust portfolio of 39 issued and 31 pending patents as well as exclusive licenses from Stanford University for key IP used in sequencing products, giving them a wide moat against competitors.
The saleable assets also include first-generation sequencing instruments and experimental prototypes that were produced by Genapsys after multiple years of R&D. Sequencing Health also recently developed multi-application biosensor machines (known as “lab on a chip” machines) that are available for sale. The Genapsys instruments and the new biosensor machines use the same semiconductor-based technology, allowing for wide usability.
See Summary Memo Link below for information on the Company. Rock Creek has been retained to sell the intellectual property assets of the Company. We will consider all offers of interest. Term sheets, evidence of ability to close, and a draft asset purchase agreement (with a schedule of assets to be purchased) will be due no later than Tuesday, July 11th, at 5 pm ET, but we will accept indications of interest prior to that time. We require an executed Confidentiality Agreement (see NDA link below) to provide access to a Confidential electronic data room with more company information.
If there is another person at your firm who would be more appropriate to review this matter, please let us know and/or forward this information accordingly. Also, if your firm is not interested in pursuing this opportunity, we’d appreciate knowing in order not to continue to follow up with you.
|
Heidi Lipton
Rock Creek Advisors, LLC
|
|
Jim Skelton
Rock Creek Advisors, LLC
|
|
Prakhar Sharma
Rock Creek Advisors, LLC
|
|
|
Jim Skelton
Rock Creek Advisors, LLC, Belmar, NJ
|
|
|
|
